162 related articles for article (PubMed ID: 3955197)
21. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
22. Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine.
Vree TB; van Ewijk-Beneken Kolmer EW; Verwey-van Wissen CP; Hekster YA
J Chromatogr; 1994 Feb; 652(2):161-70. PubMed ID: 8006100
[TBL] [Abstract][Full Text] [Related]
23. Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules.
Alpsten M; Bogentoft C; Ekenved G; Sölvell L
Eur J Clin Pharmacol; 1982; 22(1):57-61. PubMed ID: 7094976
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.
Dubovská D; Piotrovskij VK; Gajdos M; Krivosíková Z; Spustová V; Trnovec T
Methods Find Exp Clin Pharmacol; 1995; 17(1):67-77. PubMed ID: 7623523
[TBL] [Abstract][Full Text] [Related]
25. In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method.
Dei Cas M; Rizzo J; Scavone M; Femia E; Podda GM; Bossi E; Bignotto M; Caberlon S; Cattaneo M; Paroni R
Sci Rep; 2021 May; 11(1):10370. PubMed ID: 33990657
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers.
Viganò G; Garagiola U; Gaspari F
Int J Clin Pharmacol Res; 1991; 11(3):129-35. PubMed ID: 1809699
[TBL] [Abstract][Full Text] [Related]
27. [The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate].
Spahn H; Altmayer P; Cattarius-Korb S; Krüger B; Lang E; Mutschler E; Sörgel F
Arzneimittelforschung; 1985; 35(6):973-6. PubMed ID: 4026924
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans.
Cerletti C; Marchi S; Lauri D; Domanin M; Lorenzi G; Urso R; Dejana E; Latini R; de Gaetano G
Clin Pharmacol Ther; 1987 Aug; 42(2):175-80. PubMed ID: 3301151
[TBL] [Abstract][Full Text] [Related]
29. Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations.
Petersen T; Husted SE; Pedersen AK; Geday E
Acta Pharmacol Toxicol (Copenh); 1982 Oct; 51(4):285-91. PubMed ID: 7180498
[TBL] [Abstract][Full Text] [Related]
30. Determination of acetylsalicylic acid and salicylic acid in skin and plasma by high-performance liquid chromatography.
Pirola R; Bareggi SR; De Benedittis G
J Chromatogr B Biomed Sci Appl; 1998 Feb; 705(2):309-15. PubMed ID: 9521569
[TBL] [Abstract][Full Text] [Related]
31. The metabolism of aspirin in man: a population study.
Hutt AJ; Caldwell J; Smith RL
Xenobiotica; 1986 Mar; 16(3):239-49. PubMed ID: 3705620
[TBL] [Abstract][Full Text] [Related]
32. Rapid and sensitive determination of acetylsalicylic acid and its metabolites using reversed-phase high-performance liquid chromatography.
O'Kruk RJ; Adams MA; Philp RB
J Chromatogr; 1984 Oct; 310(2):343-52. PubMed ID: 6511852
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous determination of aspirin and salicylic acid in bulk aspirin and in plain, buffered, and enteric-coated tablets by high-pressure liquid chromatography with UV and fluorescence detectors.
Kirchhoefer RD
J Pharm Sci; 1980 Oct; 69(10):1188-91. PubMed ID: 7420289
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of an enteric coated aspirin preparation.
Day RO; Paull PD; Champion GD; Graham GG
Aust N Z J Med; 1976 Feb; 6(1):45-50. PubMed ID: 1065299
[TBL] [Abstract][Full Text] [Related]
35. Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases.
Juárez Olguín H; Flores Pérez J; Lares Asseff I; Loredo Abdalá A; Carbajal Rodríguez L
Biopharm Drug Dispos; 2004 Jan; 25(1):1-7. PubMed ID: 14716747
[TBL] [Abstract][Full Text] [Related]
36. Determination of acetylsalicylic acid and metabolites in biological fluids by high-performance liquid chromatography.
Reidl U
J Chromatogr; 1983 Feb; 272(2):325-31. PubMed ID: 6833429
[TBL] [Abstract][Full Text] [Related]
37. Single-dose evaluation of a new enteric-coated aspirin preparation.
Paull P; Day R; Graham G; Champion D
Med J Aust; 1976 Apr; 1(17):617-9. PubMed ID: 933973
[TBL] [Abstract][Full Text] [Related]
38. Low-dose acetylsalicylic acid therapy monitored with ultra high performance liquid chromatography.
Rubak P; Hardlei TF; Würtz M; Kristensen SD; Hvas AM
Clin Biochem; 2013 Aug; 46(12):988-992. PubMed ID: 23608356
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function.
Ross-Lee LM; Elms MJ; Cham BE; Bochner F; Bunce IH; Eadie MJ
Eur J Clin Pharmacol; 1982; 23(6):545-51. PubMed ID: 7160424
[TBL] [Abstract][Full Text] [Related]
40. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid.
Haastrup PF; Grønlykke T; Jarbøl DE
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):212-5. PubMed ID: 25469781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
